Skip to main content
ConductScienceScienceDex

Ferdinandos Skoulidis

From the FY2026 NIH awards this investigator leads as contact PI. The department is the award's.

FY2026 NIH rank #9,716
Unclaimed recordClaim profile
  • R01 Holder
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 15708312Search this ID in NIH RePORTER
ORCID iD
https://orcid.org/0000-0002-4676-4503Verified identifier for this researcher
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

FY2026 award categories

  • Internal Medicine
  • Pathology

NIH Funding · FY2026

Linked Award Amount
$2.1M
Full award amounts, FY2026
Award Records
4
Records listing this PI
Award-Linked Rank
#9,716
By linked amount among FY2026 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Ferdinandos Skoulidis. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2026 NIH portfolio memberships

NCI

National Cancer Institute

$2.1M

4 awards · administering

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2026 award records by amount

NIH award records listing Ferdinandos Skoulidis as a PI. Multi-PI records show the full award amount for context.

  • 5R01CA279452-03R01Co-investigator
    Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor
    UT MD Anderson Cancer Center · Internal Medicine (NIH department code)
    $672K
    award amount
  • 1R01CA301423-01A1R01Co-investigator
    Elucidating roles of the CD24 ligand in early lung cancer development, immune evasion and response to KRAS-targeted therapy
    UT MD Anderson Cancer Center · Pathology (NIH department code)
    $669.5K
    award amount
  • 5R01CA272570-04R01Contact PI
    Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancer
    UT MD Anderson Cancer Center · Internal Medicine (NIH department code)
    $370.6K
    award amount
  • 5R01CA279194-04R01Contact PI
    Dissecting and targeting tumor-TME crosstalk to forestall acquired KRASG12C inhibitor resistance in NSCLC.
    UT MD Anderson Cancer Center · Internal Medicine (NIH department code)
    $370.6K
    award amount

Award organization

Organizations that administered FY2026 awards listing Ferdinandos Skoulidis as a PI.

FY2026 award administered by UT MD Anderson Cancer Center (TX).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    UT MD Anderson Cancer Center
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    Entered Top 50% Nationally
    Ranked #6920
  5. 2025
    $2M Cumulative Funding
  6. 2025
    R01 Grant Holder
  7. 2026
    $5M Cumulative Funding

Shared-award investigators

Other investigators listed on at least one of the same NIH award records as Ferdinandos Skoulidis.

David John Tweardy
UT MD Anderson Cancer Center
3
shared awards
Seyed Javad Mirhassani Moghaddam
UT MD Anderson Cancer Center
3
shared awards
Humam Kadara
UT MD Anderson Cancer Center
1
shared award

Explore further

Find collaborators for Ferdinandos Skoulidis

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →